⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195917 | 1.00 | — | — | |
| SCHEMBL1579034 | 1.00 | — | — | |
| SCHEMBL554844 | 0.92 | — | — | |
| SCHEMBL665223 | 0.81 | — | — | |
| SCHEMBL145312 | 0.81 | — | — | |
| SCHEMBL668050 | 0.81 | — | — | |
| SCHEMBL554942 | 0.77 | — | — | |
| SCHEMBL2040204 | 0.65 | — | — | |
| SCHEMBL9821231 | 0.65 | ALDH1A1 (0.39) | — | |
| SCHEMBL467961 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151218-A1 | LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS | Boehringer Ingelheim International GmbH (DE) | 2023-03-22 | — | — | EP | claimed |
| EP-4104838-A1 | Use of DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | claimed |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-06-16 | — | — | US | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| CN-112656945-A | Treatment of diabetes in patients unsuited for metformin therapy | 勃林格殷格翰国际有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-07-16 | — | — | US | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| EP-3517539-A1 | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, ITS PREPARATION AND ITS USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TYPE I AND II DIABETES | Boehringer Ingelheim International GmbH (DE) | 2019-07-31 | — | — | EP | claimed |
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | claimed |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
| WO-2005026148-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | claimed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |